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Background: Patients with traumatic brain injury (TBI) exhibit a variable and
unpredictable outcome. The proteins interleukin 10 (IL-10) and heart fatty acid-binding
protein (H-FABP) have shown predictive values for the presence of intracranial lesions.
Aim: To evaluate the individual and combined outcome prediction ability of IL-10 and
H-FABP, and to compare them to the more studied proteins S100β, glial fibrillary acidic
protein (GFAP), and neurofilament light (NF-L), both with and without clinical predictors.
Methods: Blood samples from patients with acute TBI (all severities) were collected
<24 h post trauma. The outcome was measured >6 months post injury using the
Glasgow Outcome Scale Extended (GOSE) score, dichotomizing patients into: (i) those
with favorable (GOSE≥5)/unfavorable outcome (GOSE≤4) and complete (GOSE =
8)/incomplete (GOSE≤7) recovery, and (ii) patients with mild TBI (mTBI) and patients
with TBIs of all severities.
Results: When sensitivity was set at 95–100%, the proteins’ individual specificities
remained low. H-FABP showed the best specificity (%) and sensitivity (100%) in
predicting complete recovery in patients with mTBI. IL-10 had the best specificity
(50%) and sensitivity (96%) in identifying patients with favorable outcome in patients
with TBIs of all severities. When individual proteins were combined with clinical
parameters, a model including H-FABP, NF-L, and ISS yielded a specificity of 56%
and a sensitivity of 96% in predicting complete recovery in patients with mTBI.
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In predicting favorable outcome, a model consisting IL-10, age, and TBI severity reached
a specificity of 80% and a sensitivity of 96% in patients with TBIs of all severities.
Conclusion: Combining novel TBI biomarkers H-FABP and IL-10 with GFAP, NF-L and
S100β and clinical parameters improves outcome prediction models in TBI.
Keywords: biomarker, heart fatty-acid binding protein, interleukin 10, panel, protein, outcome, traumatic
brain injury
INTRODUCTION
Patients with TBI may suffer from different levels and persistence
of cognitive, behavioral, emotional, and physical impairments
(1, 2). These impairments are frequent in patients with moderate
and severe TBI, while, in cases of mild TBI (mTBI), most
of the patients recover within weeks to months after the
injury. However, a significant subgroup of patients with mTBI
shows incomplete recovery (3–5). Despite these post-traumatic
symptoms, structural brain damage in this population is often
not seen using current clinical imaging modalities. The problem
is significant worldwide, as mTBI accounts for 80–90% of all cases
with TBI (6).
Different blood-based biomarkers have been suggested as
outcome predictors of TBI to improve clinicians’ abilities to
optimize clinical care. Among the most studied biomarkers
are the astroglial proteins S100 calcium-binding protein B
(S100β), glial fibrillary acidic protein (GFAP), and the axonal
protein neurofilament light (NF-L) (7–13). Other proteins, such
as the anti-inflammatory protein interleukin 10 (IL-10) and
the brain injury marker heart fatty acid-binding protein (H-
FABP), have recently gained in interest as diagnostic tools
for TBI, but little is known about their abilities as outcome
predictors (14, 15).
To date, most biomarker studies have investigated
proteins’ individual prediction abilities. Considering the
pathophysiological complexity of TBI, single biomarkers tend
to have low prediction capacities, and they may therefore not be
optimal for clinical use (16). To improve the accuracy, combining
several biomarkers together or combining biomarker(s) with
clinical parameters have been suggested, thus producing
models of several predictive markers (16, 17). These kinds
of models have already shown to significantly increase the
predictive power compared to single markers in different
diseases, such as aneurysmal subarachnoid hemorrhage, lung
cancer, and sleeping sickness (18–21). Recent studies have
also highlighted the beneficial use of panels as diagnostic
tools for mTBI (22, 23) and for predicting the need for acute
head imaging following TBI (24). Furthermore, combining
inflammatory proteins together with brain-derived ones
may improve the ability to predict outcome after TBI
(25, 26).
The aim of the present study was to compare the proteins
IL-10 and H-FABP to the well-studied proteins S100β, GFAP,
and NF-L for their individual ability to predict patients who
will have favorable long-term outcome analyzing patients on a
clinically meaningful allocation basis: patients with mTBI and
patients with TBIs of all severities. In order to demonstrate the
added value of blood biomarkers in addition to clinical variables,
we analyzed the biomarkers in isolation and with clinical
variables recorded upon admission. Furthermore, combinations
of predictive markers were evaluated in an attempt to increase
this prediction ability.
MATERIALS AND METHODS
Study Population and Clinical Variables
In this single-center study, patients were recruited at Turku
University Hospital (a tertiary care university hospital with a
combined primary and tertiary care emergency department)
in Finland between the years 2011–2013. All the consecutive
patients with TBI were evaluated for eligibility to be recruited
in the study by the research team between 8 a.m. to 10 p.m. To
be included in the study, the following inclusion criteria needed
to be fulfilled; age ≥18 years, hospital admission within 24 h
after trauma, clinical diagnosis of a TBI with an indication for
a head computed tomography (CT) scan according to the NICE
criteria (27) as judged by an emergency physician on call, and
outcome data at 6–12 months after injury had to be available.
Exclusion criteria were penetrating or blast-induced injury,
chronic subdural hematoma, inability to live independently due
to a previous brain disease, no performed CT scan, or no
written consent.
The ethical review board of Hospital District of South-West
Finland approved the study protocol (decision 68/180/2011).
Written informed consent was obtained from all participants or
their legal representatives prior to inclusion.
The outcomes were assessed by single experienced neurologist
(OT) using the Glasgow Outcome Scale Extended (GOSE) (28).
The total injury burden was assessed with Injury Severity Score
(ISS) (29).
Head Imaging and Traumatic Brain Injury
Severity Classifications
Head CT scans were classified according to the Marshall
classification system (30). Neuroradiologists at the Turku
University Hospital and a senior neurosurgeon (JPP) double-
read the CT scans.
In addition to using the lowest Glasgow Coma Scale (GCS)
score before possible intubation, either at the scene of accident or
emergency department (31), TBI severity was also classified using
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an aggregate covariate combining the lowest GCS and the length
of post-traumatic amnesia1.
Protein Measurement
Serum samples were drawn within 24 h after trauma. However,
as these different time points did not appear to correlate with
biomarker levels, all of them were considered as a common time
point. Only admission samples were assessed. After obtaining
the blood samples, the samples were centrifuged and stored
at −70 ◦C. The proteins GFAP and NF-L were measured
using the Human Neurology 4-plex A assay (N4PA) on HD-1
single molecule array (Simoa) device fromQuanterix (Lexington,
MA, USA). The lower limit of quantification (LLoQ) for each
kit was 0.104 pg/mL for NF-L and 0.221 pg/mL for GFAP.
The protein S100β was measured using the EZHS100B-33K
kit from Millipore (Millipore, Billerica, MA, USA) with an
LloQ of 2.74 pg/mL. H-FABP and IL-10 were analyzed using
the K151HTD and K151QUD kits, respectively, Meso Scale
(Meso Scale Diagnostics, Rockville, MD, USA). The LloQ for H-
FABP was 0.137 ng/mL and for IL-10 0.298 pg/mL. All proteins
were measured according to manufacturers’ recommendations
by board-certified laboratory technicians who were blinded to
clinical data.
Statistical Analysis
Statistical analyses were performed to evaluate the proteins’
outcome prediction ability defined by the GOSE score. The
patients were dichotomized in two different groups: (a) the
first one included TBI patients of all severities (worst GCS
3–15, n = 88), while the second one (b) included only the
subgroup of mTBI (worst GCS 13–15, n = 49) patients. The
GOSE was dichotomized into (a) 1–4 for unfavorable outcome
or 5–8 for favorable outcomes for all severity patients and (b)
1–7 for incomplete recovery or 8 for complete recovery for
mTBI patients. These dichotomizations were chosen because the
favorable/unfavorable outcome is relevant for TBIs in general
(especially moderate—severe TBIs) and complete/incomplete for
those with mTBI. Non-parametric tests were used because all
proteins were non-normally distributed, as indicated by the
Kolmogorov-Smirnov test (p < 0.05). Therefore, to evaluate
the proteins’ differences between groups, the Mann-Whitney
U test was performed using IBM SPSS software, version 24.0
(SPSS Inc., Chicago, IL, USA). The proteins’ outcome prediction
capacities were evaluated using the partial area under a receiver
operating characteristic cure (pAUC), which allowed us to focus
only in the interest region of the ROC curve. Analysis were
computed using TIBCO Spotfire S+ R© version 8.2 software
(TIBCO Software Inc., Palo Alto, CA, USA). Model selections
were done using the PanelomiX toolbox based on the iterative
combination of biomarkers/variables and thresholds method
(ICBT) (32). To make the process faster, several biomarkers (H-
FABP, IL-10, S100β, NF-L, and GFAP)/variables (age, Marshall
grade, Injury Severity Score, Severity, and GCS) were tested
together. PanelomiX used the random forest method to select
the different thresholds. Cross validation and ROC analysis
1https://www.healthquality.va.gov/guidelines/Rehab/mtbi/
mTBICPGFullCPG50821816.pdf
were used to evaluate the performance of the model. In this
manuscript, a maximum number of three biomarkers or clinical
parameters in each model were investigated. The PanelomiX tool
established the best cut-off for each single biomarker, and the best
combinations were investigated when the sensitivity was set at
95–100% in order to reduce the false negative cases.
RESULTS
Study Population
A total of 88 TBI patients with blood samples available within 24
from the time of injury were included in this study, and 69% of
the patients were male. The most common causes of trauma were
falls and traffic accidents. The distributions of severity, imaging
findings, and outcome are shown in Table 1.
Complete Recovery – Patients With mTBI
We first investigated the proteins’ individual capacities to predict
complete recovery in patients with mTBI. All these proteins
tended to be higher in patients with incomplete recovery (GOSE
≤ 7, n = 24) compared to those with complete recovery (GOSE
8, n = 25), although these findings were without significance.
The proteins were investigated when the sensitivity was set
at 95–100%. The individual specificities remained low. The
best performing protein was H-FABP, reaching 4% specificity
and 100% sensitivity. NF-L and S100β had somewhat higher
specificities of 12% but lower sensitivities of 96% (Table 2).
Next, combinations of proteins to increase the ability to
predict complete recovery were evaluated. The best two-protein
panel was a combination of H-FABP and NF-L, reaching a
specificity of 40% and sensitivity of 96%, thus resulting in a 36-
percentage point increase in specificity compared to the best
performing single protein H-FABP. A panel comprising three
proteins—H-FABP, GFAP, and NF-L—was further capable of
increasing the specificity to 44% with 96% sensitivity (Table 3).
Combining individual proteins with clinical parameters
was also evaluated to predict complete recovery (Table 3).
Combination of H-FABP, the most specific molecule in isolation,
with clinical parameters showed an improved performance over
proteins alone. Maintaining a value of 96% sensitivity, the
combination of H-FABP, NF-L, and TBI severity reached a
specificity value of 56%, which is far better than for H-FABP
alone (Table 3). The individual outcome prediction capacities of
clinical parameters are presented in Supplementary Table 1.
Favorable Outcome – Patients With TBIs of
All Severities
H-FABP, IL-10, S100β, NF-L, and GFAP were evaluated for their
individual capacities to predict favorable outcome in patients
with TBIs of all severities. The blood levels of all proteins studied
were significantly higher in patients with unfavorable outcome
(GOSE ≤ 4, n = 28) compared to those with favorable outcome
(GOSE ≥ 5, n = 60) (p ≤ 0.001). Again, the ability of each
biomarker for the detection of favorable outcome was evaluated
when the protein reached 95–100% sensitivity. According to
these criteria, the best performing protein was IL-10, with a
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TABLE 1 | Characteristics of the study patients.
TBI all severities Mild TBI
Complete recovery Favorable outcome Complete recovery Favorable outcome
GOSE 8 GOSE 1–7 GOSE 5–8 GOSE 1–4 GOSE 8 GOSE 1–7 GOSE 5–8 GOSE 1–4
(n = 25) (n = 63) (n = 60) (n = 28) (n = 25) (n = 24) (n = 45) (n = 4)
Age
Mean (SD) 40.9 (20.27) 51.13 (18.39) 44 (18.68) 57.25 (18.02) 40.9 (20.3) 47.5 (18.7) 43.4 (19.6) 52.8 (20.9)
Gender
Male, n (%) 17 (68) 44 (69.8) 43 (71.7) 18 (64.3) 17 (68) 9 (37.5) 31 (68.9) 1 (25)
Marshall Grade, n (%)
No visual pathology (grade 1) 17 (68) 18 (28.6) 33 (55) 2 (7.1) 17 (68) 11 (45.8) 28 (62.3) 0 (0)
Diffuse injury (grade 2) 4 (16) 11 (17.5) 11 (18.3) 4 (14.3) 4 (16) 9 (37.5) 10 (22.2) 3 (75)
Diffuse injury with swelling (grade 3) 0 (0) 1 (1.6) 0 (0) 1 (3.6) 0 (0) 0 (0) 0 (0) 0 (0)
Diffuse injury with shift (grade 4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Evacuated mass lesion (grade 5) 1 (4) 22 (34.9) 9 (15) 14 (50) 1 (4) 1 (4.2) 2 (4.4) 0 (0)
Non evacuated mass lesion (Grade 6) 3 (12) 11 (17.5) 7 (11.7) 7 (25) 3 (12) 3 (12.5) 5 (11.1) 1 (25)
Injury Severity Score (ISS), n (%)
Minor 1–8 16 (64) 13 (20.6) 27 (45) 2 (7.1) 16 (64) 10 (41.7) 25 (55.6) 1 (25)
Moderate 9–15 4 (16) 15 (23.8) 13 (21.6) 6 (21.4) 4 (16) 8 (33.3) 10 (22.2) 2 (50)
Serious 16–24 4 (16) 16 (25.3) 12 (20) 8 (28.6) 4 (16) 4 (16.7) 7 (15.6) 1 (25)
Severe 25–49 1 (4) 17 (26.9) 7 (11.7) 11 (39.3) 1 (4) 2 (8.3) 3 (6.7) 0 (0)
Critical 50–74 0 (0) 1 (1.6) 1 (1.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Maximum 75 0 (0) 1 (1.6) 0 (0) 1 (3.6) 0 (0) 0 (0) 0 (0) 0 (0)
*Severity, n (%)
Very mild 1 1 (4) 0 (0) 1 (1.7) 0 (0) 1 (4) 0 (0) 1 (2.2) 0 (0)
Mild 2 23 (92) 27 (42.9) 45 (75) 5 (17.9) 23 (92) 18 (75) 39 (8.7) 2 (50)
Moderate 3 0 (0) 12 (19.1) 7 (11.7) 5 (17.9) 0 (0) 4 (16.6) 3 (6.7) 1 (25)
Severe 4 1 (4) 10 (15.9) 5 (8.2) 6 (21.4) 1 (4) 1 (4.2) 1 (2.2) 1 (25)
Very severe 5 0 (0) 12 (19.1) 1 (1.7) 11 (39.3) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown - 2 (3.1) 1 (1.7) 1 (3.6) 0 (0) 1 (4.2) 1 (2.2) 0 (0)
GCS, n (%)
Mild 13–15 25 (100) 24 (38.1) 45 (75) 4 (14.2) 25 (100) 24 (100) 45 (100) 4 (100)
Moderate 9–12 0 (0) 24 (38.1) 12 (20) 12 (42.9) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 3–8 0 (0) 15 (23.8) 3 (5) 12 (42.9) 0 (0) 0 (0) 0 (0) 0 (0)
Time from injury to blood sampling
Mean, hours (SD) 6.2 (5.7) 9.9 (6.1) 9.8 (6.1) 12.3 (6.6) 6.2 (4.8) 12.9 (5.7) 9 (10.3) 14 (4.6)
*Severity combined from GCS and duration of posttraumatic amnesia, see ref1.
sensitivity reaching 96% and specificity of 50%. The proteins H-
FABP and GFAP performed similarly, with sensitivities of 96%
for both and specificities of 30% and 28%, respectively (Table 4).
The proteins’ performances were also evaluated when they
were combined in panels and when they were combined
with clinical parameters. Individual performances of clinical
parameters are presented in Supplementary Table 2.
The best combination using two proteins was IL-10 and H-
FABP. This panel was capable of reaching 96% sensitivity and
58% specificity. This combination increased the specificity with
8 percentage points compared to the best single molecule IL-10.
The best performing panel combining three proteins included
IL-10, H-FABP, and GFAP. This panel managed to maintain
the sensitivity at 96% and to increase the specificity up to 63%
(Table 5).
The combination of individual proteins with clinical
parameters improved the predictive ability compared to
predictions using only protein biomarkers. Combining IL-10, the
most specific protein, with patient’s age and TBI severity reached
80% specificity with 96% sensitivity, which produces an increase
in the specificity of 30 percentage points when comparing with
the best single protein marker (Table 5).
DISCUSSION
Reliable early prediction of the patient’s outcome in TBI
can help clinicians in their decision-making and thereby
optimize the care cost-effectively. Different blood biomarkers
have previously been suggested as objective outcome predictor
tools. This prospective, observational study of patients with
acute TBI showed the potential benefits of using novel TBI
biomarkers IL-10 and H-FABP but also previously studied
biomarkers GFAP (13, 33), S100β (34), and NF-L (11,
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33, 35) as individual predictive biomarkers for promising
outcome prediction; this also showed that models including
previously known robust clinical predictors may further improve
the accuracy.
According to the results presented in this manuscript we
can highlight that blood biomarkers have a strong outcome-
predictive capacity in patients with TBI and more importantly
that the combination with other biomarkers or clinical
parameters enhances this precision.
The present study has shown that, in mTBI patients, among
all the tested proteins, H-FABP exhibits the best capacity in
discriminating patients with complete and incomplete recovery.
This protein was also selected among the most promising
ones when the predictive capacity of panel of proteins was
evaluated; the combination of GFAP, H-FABP, and NF-L reached
a specificity value of 40% when the sensitivity was set at 95–
100%. Furthermore, as previously stated, inclusion of different
clinical covariates showed to importantly augment the outcome
prediction capacity of the proteins. Models including H-FABP,
NF-L, and ISS yielded a specificity of 56%
TABLE 2 | Performance of single proteins when differentiating between complete
(GOSE 8) and incomplete (GOSE ≤ 7) recovery in patients with mTBI.
% pAUC
(95% CI)
Threshold %SP (95% CI) 95–100 %SE
(95% CI)
H-FABP 0.2 (0.0–0.7) 44.9 4.0 (0.0–12) 100 (100–100)
NF-L 0.1 (0.0–1.2) 4.85 12 (0.0–24.1) 95.8 (87.5–100)
S100β 0.1 (0.0–1.0) 23.17 12 (0.0–28.0) 95.8 (87.5–100)
IL-10 0.0 (0.0–0.7) – 0.0 (0–0) 100 (100–100)
GFAP 0.0 (0.0–0.6) – 0.0 (0–0) 100 (100–100)
Biomarkers are shown according to their specificity obtained at 95–100% sensitivity.
pAUC, partial area under the curve; SP, specificity; SE, sensitivity; IL-10, interleukin
10; H-FABP, heart fatty-acid binding protein; GFAP, glial fibrillary acidic protein; NF-L,
neurofilament light; S100β, S100 calcium-binding protein B. All threshold concentrations
are in pg/mL except for H-FABP which is in ng/mL.
In regard to patients with TBIs of all severities, IL-10 has the
best capacity to discriminate favorable and unfavorable outcome;
however, similarly to the mTBI population, the specificities of
all proteins studied remained ≤50% when studied in isolation.
Based on these findings, we again studied the proteins in panels
fixing the sensitivity at 95–100%, which allowed us to find that the
combination of GFAP, H-FABP, and IL-10 reached a specificity
value of 63%. Once again, the inclusion of clinical covariates
drastically improved the results reaching a specificity of 80%
when IL-10, age and TBI were combined together.
Briefly, the current results indicate that of all studied proteins
H-FABP has the best capacity to predict complete recovery
and IL-10 to predict favorable outcome. In all two- and three-
biomarker panels, either H-FABP and IL-10 were included. These
markers have previously been shown efficient as CT scan triage
tool for patients with mild TBI (22).
The protein H-FABP is a small cytoplasmic protein that leaks
out from injured endothelial cells and neuronal cell bodies. It
is a well-known myocardial infarction biomarker, and, even if
it is not a TBI specific marker, increased levels have previously
TABLE 4 | Performance of single proteins when differentiating between favorable
(GOSE 5–8) and unfavorable (GOSE 1–4) outcomes in all severity patients.
% pAUC (95% CI) Threshold %SP (95% CI) 95-100 %SE (95% CI)
IL-10 1.4 (0.7–3.0) 0.39 50.0 (36.7–63.3) 96.4 (89.3–100)
H-FABP 1.1 (0.6–2.7) 4.31 30.0 (18.3–41.7) 96.4 (89.3–100)
GFAP 0.8 (0.3–2.3) 415 28.3 (16.7–40.0) 96.4 (89.3–100)
NFL 0.5 (0.2–4.4) 5.47 10.0 (3.3–18.3) 100 (100–100)
S100β 0.1 (0–1.4) 23.17 6.7 (1.7–13.3) 96.4 (89.3–100)
Biomarkers are shown in order according to their specificity obtained at 95–100%
sensitivity. Mann U, Mann-Whitney U-test; pAUC, partial area under the curve; SP,
specificity; SE, sensitivity; IL-10, interleukin 10; H-FABP, heart fatty-acid binding protein;
GFAP, glial fibrillary acidic protein; NF-L, neurofilament light; S100β, S100 calcium-binding
protein B. All threshold concentrations are in pg/mL except for H-FABP, which is in ng/mL.
TABLE 3 | Panels performed in patients with mTBI, including proteins (H-FABP, IL-10, GFAP, S100β, and NF-L) or proteins and clinical parameters: Marshall grade,
severity, injury severity score, and age.
Panel Markers cut-off n GOSE 8 n GOSE <7 % SP (95% CI) % SE (95% CI)
2 Parameters (only proteins) H-FABP (6.26) 25 24 40.0 (20.0–60.0) 95.8 (87.5–100)
NF-L (15.9)
3 Parameters (only proteins) H-FABP (5.01) 25 24 44.0 (24.0–64.0) 95.8 (87.5–100)
NF-L (13.46)
GFAP (2457.5)
2 Parameters (proteins/clinical parameters) H-FABP (6.26) 25 24 40.0 (20.0–60.0) 95.7 (87.0–100)
NF-L (15.9)
3 Parameters (proteins/clinical parameters) H-FABP (4.30) 25 24 56.0 (36.0–76.0) 95.7 (87.0–100)
NF-L (13.46)
Severity (2.5)
Complete recovery GOSE 8 and incomplete recovery GOSE ≤ 7; SP, specificity; SE, sensitivity. All protein cut-off concentrations are in pg/mL except for H-FABP, which is in ng/mL.
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TABLE 5 | Panels including only proteins (H-FABP, IL-10, GFAP, S100β, and NF-L) or proteins and clinical parameters (Marshall grade, severity, injury severity score, age,
and GCS).
Panel Markers cut-off n GOSE≥5 n GOSE≤4 % SP (95% CI) % SE (95% CI)
2 Parameters (only proteins) IL-10 (0.38) 60 28 58.3 (45.0–71.7) 96.4 (89.3–100)
H-FABP (4.31)
3 Parameters (only proteins) IL-10 (0.38) 60 28 63.3 (51.7–75.0) 96.4 (89.3–100)
H-FABP (4.31)
GFAP (145.13)
2 Parameters (proteins/clinical parameters) NF-L (41.5) 59 27 72.9 (61–84.7) 96.3 (88.9–100)
Severity (2.5)
3 Parameters (proteins/clinical parameters) IL-10 (0.44) 59 27 79.7 (69.5–89.8) 96.3 (88.9–100)
Age (61)
Severity (2.5)
Favorable outcome GOSE ≥5 and unfavorable outcome GOSE ≤4; SP, specificity; SE, sensitivity. All protein cut-off concentrations are in pg/mL except for H-FABP, which is in ng/mL.
been shown in patients with severe TBI and poor outcome
(36–39). IL-10 or human cytokine synthesis inhibitory factor
is a potent anti-inflammatory cytokine mainly produced by
macrophages, B cells, and dendritic cells. Similarly, it is not a
brain-specific marker, but the levels have also been shown to be
increased in patients with severe TBI and poor outcome (40).
Literature on the prognostic value of both H-FABP and IL-
10 is scarce. The previous reports on the outcome prediction
ability of IL-10 after TBI are contradictory, though it has shown
some potential in the prediction of mortality—the past studies
have been very heterogenic in their methods (41). Intriguingly,
the best-performing three-biomarker panel in discriminating
patients with favorable and unfavorable outcome in patients
with TBIs of all severities (GFAP, H-FABP, and IL-10) was the
same that we have previously reported to be the best panel
in detecting patients with CT-positive findings in the groups
of patients with TBIs of all severities and patients with mTBIs
without extracranial injuries (24). Because all these studies are
from the same patient population, further studies should confirm
if these combinations perform best also in other patients with
acute TBI.
Several different pathophysiological processes can affect
the outcome of TBI, such as apoptosis, blood brain barrier
damage, and neuroinflammation (42). TBI is a complex
pathophysiological disease where single markers may never
be accurate enough for clinical applications (43). Combining
biomarkers from different pathophysiological pathways has
previously been shown to increase the overall accuracy (16, 24).
Among other clinical parameters, such as age, Marshall grade, or
ISS, we chose to include both the GCS score and TBI severity
(an aggregate covariate) to the predictive models consisting of
clinical covariates and biomarkers because we hypothesized that
it would better reflect the importance of PTA in combination
with the GCS score. As seen in the results, TBI severity is
included more often in the predictive models than the GCS
score alone. The prediction capacity of biomarkers is usually
evaluated using the total AUC value; however, this entire value
of ROC curve evaluates regions that usually are not relevant to
clinical applications. Therefore, in order to avoid this drawback
we decided to focus on pAUC, evaluating specificity values only
when the sensitivity was fixed between 95 and 100% (44).
The model selection method used in this manuscript,
PanelomiX, has been shown to have several advantages over
other already known selection methods, such as random forest,
support vector machine or logistic regression. It has provided us
the selection of best biomarkers specifying their optimal cut-off
points (obtained by cross-validation). Obtained results are easy to
interpret for the clinicians, which is another important advantage
over other traditional black-box methods, and furthermore the
prediction performances of panels obtained using PanelomiX
tool are similar to that obtained with support vector machine
among others.
This study has several limitations. Blood samples were
collected within the first 24 h after trauma, which could be too
late for the measurement of several biomarkers as S100β and
GFAP (24, 45). The optimal biomarker panel is probably greatly
dependent on both the time from injury and type of injury,
and this is why further studies are necessary to clarify which
biomarkers or biomarker combinations perform best at different
points of time in different TBI populations. There is also some
evidence that the clinical usability of biomarkers may depend
on the age of the patient (46). Furthermore, the cohort used
here included only 88 patients with TBI, making multivariate
analysis of the molecules inconvenient according to the Monte
Carlo study (47). The fairly small study population also increases
the risk of over-fitting bias, which is why the results should
be verified and validated in a larger cohort. Our study cohort
included patients with TBI of all the severities where 56% had
mTBI and 17% had severe TBI. For the whole cohort, the results
may be partly driven by the more severe cases of TBI due to
their higher biomarker levels, and, on the other hand, our cases
of mTBI were more severe than patients with mTBI as a whole
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since most of our cases had been admitted to neurosurgical
ward. We chose to study patients with mTBI and TBIs of all
severities independently because (i) patients with mTBI are a
distinctive group of patients with specific diagnostic needs, and
(ii) examining the outcome prediction ability in patients with
all severities is important because initial severity of a TBI is
not always clear due to possible confounding factors (such as
intoxication, hypoglycemia, and neurological diseases).
Moreover, using GOSE as an outcome measure is a relatively
insensitive way to detect subtle impairments in patients with
mTBI or in TBI in general since it will miss many important and
subtle deficits and it may be affected also by factors not directly
related to the anatomical brain injury itself. The usability of IL-10
and H-FABP should be studied using a higher number of patients
with different clinical characteristics.
CONCLUSION
The novel proteins IL-10 and H-FABP in TBI diagnostics
show promise in detecting patients with either favorable
outcome or complete recovery following TBI. Combining
levels of these proteins and NF-L with clinical covariates
may assist in clinical decision-making at the emergency
department and stratification for different monitoring and
treatment algorithms.
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